APLN and sarcopenia: These findings suggest that, contrary to earlier studies in cellular and animal models where apelin demonstrated a beneficial impact on muscle metabolism, such effects may not translate to the human context, and contribute valuable clinical evidence indicating that serum apelin may not serve as a reliable biomarker for sarcopenia.